Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 19, 2010 - Issue 12
Submit an article Journal homepage
322
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluations

Delayed release phosphatidylcholine as new therapeutic drug for ulcerative colitis – a review of three clinical trials

Wolfgang Stremmel University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MD,
Anja Hanemann University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MS,
Annika Braun University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MD,
Sabine Stoffels University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MD,
Max Karner University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MD,
Sahar Fazeli University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MD &
Robert Ehehalt University Hospital Heidelberg, Department of Gastroenterology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany +49 6221 568705; +49 6221 564116; wolfgang_stremmel@med. uni-heidelberg.de
, MD show all
Pages 1623-1630 | Published online: 25 Nov 2010

Bibliography

  • Hoffmann JC, Zeitz M, Bischoff SC, Diagnostik und therapie der colitis ulcerosa: Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft fur Verdauungs- und Stoffwechselerkrankungen zusammen mit dem Kompetenznetz chronisch entzundliche Darmerkrankungen. Z Gastroenterol 2004;42:979-83
  • Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-34
  • Abraham C, Cho JH. Mechanisms of disease. Inflammatory bowel disease. N Engl J Med 361;21:2066-78
  • Balfour Sartor R. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-94
  • Rutgeerts P, Sandborn WJ, Feagan BG, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
  • Summers RW, Elliott DE, Urban JF, Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterol 2005;128:825-32
  • Kruis W, Fric P, Pokrotnieks J, Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617-23
  • Ukena SN, Singh A, Dringenberg U, Probiotic escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One 2007;2(12):e1308
  • Mondel M, Schroeder BO, Zimmermann K, Probiotic escherichia coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009;2(2):166-72
  • Backhed F, Ley RE, Sonnenburg JL, Host-bacterial mutualism in the human intestine. Science 2005;307:1915-20
  • Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001;280(5):G922-9
  • DeSchryver-Kecskemeti K, Eliakim R, Carroll S. Intestinal surfactant-like material. A novel secretory product of the rat enterocyte. J Clin Invest 1989;84(4):1355-61
  • Butler BD, Lichtenberger LM, Hills BA. Distribution of surfactants in the canine gastrointestinal tract and their ability to lubricate. Am J Physiol 1983;244(6):G645-51
  • Hicks AM, DeLong CJ, Thomas MJ, Unique molecular signatures of glycerophospholipid species in different rat tissues analyzed by tandem mass spectrometry. Biochim Biophys Acta 2006;1761(9):1022-9
  • Hills BA. Surface-active phospholipid: a Pandora's box of clinical applications. Part II. Barrier and lubricating properties. Intern Med J 2002;32(5-6):242-51
  • Lichtenberger LM. The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 1995;57:565-83
  • Willumeit R, Schuster A, Iliev P, Phospholipids as implant coatings. J Mater Sci Mater Med. 2007;18:367-80
  • Guo W, Andersson R, Odselius R, Phospholipid impregnation of abdominal rubber drains: resistance to bacterial adherence but no effect on drain-induced bacterial translocation. Res Exp Med (Berl) 1993;193:285-96
  • Ehehalt R, Jochims C, Lehmann WD, Evidence of luminal phosphatidylcholine secretion in rat ileum. Biochim Biophys Acta 2004;1682:63-71
  • Ehehalt R, Wagenblast J, Erben G, Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39:737-42
  • Braun A, Treede I, Gotthardt D, Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 2009;15:1705-20
  • Braun A, Schoenfeld U, Welsch T, The surface hydrophobicity of the colonic mucosa is reduced in ulcerative colitis. J Crohn's and Colitis 2010;4:S24-5
  • Stremmel W, Hanemann A, Ehehalt R. Phosphatidylcholine (lecithin) and the mucus layer: evidence of therapeutic efficacy in ulcerative colitis? Dig Dis 2010;28:490-6
  • Ehehalt R, Braun A, Karner M, Phosphatidylcholine as a constituent in the colonic mucosal barrier – physiological and clinical relevance. Biochim Biophys Acta 2010;1801:983-93
  • Stremmel W, Merle U, Zahn A, Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54:966-71
  • Stremmel W, Braun A, Hanemann A, Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol 2010;44(5):e101-7
  • Stremmel W, Ehehalt R, Autschbach F, Karner M. Efficacy of retarded release phosphatidylcholine for treatment of chronic, steroid refractory ulcerative colitis. Ann Intern Med 2007;147:603-10
  • Karmer M. A study to investigate the efficacy of LT-02 in patients with mesalazine refractory ulcerative colitis. 2009. Available from: http://www.clinicaltrials.gov./ct2/ show/NCT01011322?term=NCT01011322.&rank=1 [Last accessed 27 October 2010]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.